Inovio Pharmaceuticals Reports Results From Phase 1 Clinical Trial of Coronavirus Vaccine CandidateThe Motley Fool • 06/30/20
Inovio Plunges On Interim Phase 1 Coronavirus Data; DNA Vaccine Shows 94% Response RateBenzinga • 06/30/20
Inovio's stock falls as it discloses early-stage data for its COVID-19 vaccine candidateMarket Watch • 06/30/20
INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19PRNewsWire • 06/30/20
Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After RallyBenzinga • 06/29/20
Inovio's stock surges to extend rally to 20-year high, while Stifel says price is now 'less palatable'Market Watch • 06/26/20
Inovio Wins $71 Million Department of Defense Contract for Its COVID-19 Vaccine Delivery DevicesThe Motley Fool • 06/23/20